【摘要】 目的系统评价西格列汀(SITA)联合二甲双胍(MET)治疗2型糖尿病(T2DM)的疗效及不良反应。方法计算机检索Cochrane图书馆、PubMed、EMbase、中国知网、万方数据库和维普数据库,查找国内外所有比较SITA联合MET与MET单独用药治疗T2DM的随机对照试验,使用Cochrane协作网RevMan 5.2软件进行meta分析。结果共纳入12个随机对照试验,合计3 200例患者。Meta分析结果显示:SITA联合MET治疗较单用MET能有效降低糖化血红蛋白水平[WMD=-0.69%,95%CI(-0.85,-0.53),P<0.000 01]、空腹血糖水平[WMD=-0.91%,95%CI(-1.14,-0.69),P<0.000 01],同时改善胰岛素抵抗[WMD=-0.54,95%CI(-0.99,-0.10),P=0.02];在体质量指数变化、不良反应发生率方面,两组差异无统计学意义(P>0.05)。结论 SITA联合MET治疗T2DM安全有效,较单用MET能更有效地控制血糖,两者不良反应发生率差异无统计学意义。更多还原

【Abstract】 Objective To assess the effects and safety of sitagliptin( SITA) combined with metformin( MET) in treating type 2 diabetes mellitus( T2DM).Methods The Cochrane Library,PubMed,EMbase,CNKI Database,WangFang Database,and VIP Database were searched to collect the randomized controlled trials( RCTs) on SITA combined with MET versus MET in treating T2DM.meta-analysis was performed using RevMan 5.2 software in accordance with the Cochrane Collaboration.Results A total of 12 RCTs involving 3 200 patients were included.The results of meta-analysis showed that,compared to MET alone,SITA combined with MET effectively improved glycosylated hemoglobin levels [ WMD =- 0.69%,95% CI(- 0.85,- 0.53),P < 0.000 01 ] and fasting plasma glucose levels [WMD =- 0.91%,95% CI(- 1.14,- 0.69),P < 0.000 01 ],and increased insulin sensitivity and β-cell function [ WMD =- 0.54,95% CI(- 0.99,- 0.10),P = 0.02].But there were no significant differences between the two groups in body mass index and the percentage of patients with adverse events( P > 0.05).Conclusion Compared to using MET alone,SITA combined with MET can improve glycemic control,and there is no statistical difference of adverse events.更多还原